AzTrials
AzTrials

Steatosis of LiverNCT06373536

Comparison of MRI-PDFF to TAEUS FLIP Device to Estimate Liver Fat Fraction in Adults

An observational study of Steatosis of Liver, run by Endra Lifesciences at 1 site in Germany.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Primary nonalcoholic fatty Liver disease (NAFLD) is an excess of fat in the liver (steatosis) that is not a result of excessive alcohol consumption or other secondary causes11. NAFLD is defined by the presence of hepatic fat content (steatosis) in ≥ 5% of hepatocytes and is currently the most common liver disease… Read more about this study

Who is it for?
Ages 18 to 70 yearsHealthy volunteers can take part
Conditions the study is for
Steatosis of Liver
What is being tested?
Thermoacoustic imaging, MRI and Ultrasound imaging
How many people
80 participants
Where
1 siteGermany
Study dates
21 Jun 2024to 1 Sep 2025
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 70 years
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Study population: Patients referred to radiology for abdominal imaging and suspected of having steatotic liver disease.

Who may be able to join

  • Study participants are 18-70 years of age
  • Existing MRI-PDFF not older than 6 weeks or routine MRI-PDFF in the following 6 weeks
  • Be able to understand, read, and provide written informed consent in German
  • Tolerant to ultrasound and MRI examinations
  • Able to lay flat for 20 minutes

Who cannot join

  • Metal or electronic implants, including, but not limited to: pacemakers, metal clips, drug delivery pumps, hip implants, and neural stimulation devices.
  • Known pregnancy the day of consent, or becoming pregnant during study participation
  • Liver disease other than NAFLD/NASH including, but not limited to, hepatitis, cirrhosis, hepatocellular carcinoma.
  • Patients with broken, or injured skin, in the right upper abdominal quadrant.
  • BMI over 43 kg/m2

Trial locations and contacts

1 site in 1 country.

Dirk-Andre Clevert, Prof. Dr. contact

+49 89 44007 3635

Dirk.Clevert@med.uni-muenchen.de

Germany1 site
  • Klinikum der Universität München Großhadern Klinik und Poliklink für Radiologie

    München, 81377

    Monika Dienst, M.Sc., +49 89 4400 76642, monika.dienst@med.uni-muenchen.de

    Dirk-Andre Clevert, Prof. Dr. med.

Other trials in Germany

About this study

Official title: Comparison of Thermoacoustic Enhanced Ultrasound for Estimating Liver Fat Fraction to MRI-PDFF

Primary nonalcoholic fatty Liver disease (NAFLD) is an excess of fat in the liver (steatosis) that is not a result of excessive alcohol consumption or other secondary causes11. NAFLD is defined by the presence of hepatic fat content (steatosis) in ≥ 5% of hepatocytes and is currently the most common liver disease worldwide14 . Non-Alcoholic Fatty Liver Disease (NAFLD) is the world\'s most common liver disease and affects around 33% of the adult population.

Nonalcoholic steatohepatitis (NASH), a progressive form of nonalcoholic fatty liver disease (NAFLD), is a growing clinical concern associated with the increasing prevalence of obesity, type 2 diabetes, and metabolic syndrome. NASH is characterized by the presence of hepatic steatosis, inflammation, and hepatocellular injury and is predicted to be the leading indication for liver transplantation by 20201. Patients with NASH have an increased risk of developing cirrhosis and its complications, such as ascites, variceal hemorrhage, hepatic encephalopathy, hepatocellular carcinoma, and liver failure. The prevalence worldwide of NAFLD in the general population is estimated at 20-35%2 . Around 2-3% of the population have NASH.

In patients with type 2 diabetes, the prevalence is even over 50% (55.5% globally, 68% in Europe). In Germany, the NAFLD prevalence was 23% in 2016 and will be around 26% in 2030. The prevalence of non-alcoholic alcoholic steatohepatitis (NASH), i.e. the progressive form of NAFLD, is estimated at 4% of the adult population in Germany and will increase to 6% by 2030. This means that NAFLD is already the most common chronic liver disease worldwide and one of the leading causes of liver-related complications (cirrhosis, decompensation, hepatocellular carcinoma, liver transplantation) and deaths. NAFLD and NASH are largely underdiagnosed worldwide.

Read the detailed description

Early detection and surveillance of steatosis hepatis improves the chances of management or even improvement of the disease before irreversible damage occurs12. Liver tissue biopsy is the current reference standard for the diagnosis and severity of steatosis hepatis. However, due to its invasiveness, biopsy collection is not suitable for screening or regular follow-up. The diagnostic techniques of magnetic resonance spectroscopy (MRS) and MRI-PDFF (proton density fat fraction) for the assessment of liver fat content have been shown to correlate well with the results of liver biopsy, but are particularly associated with high costs, low availability, long examination times and exclusion of patients with metal implants. Conventional B-scan ultrasonography is the most commonly used imaging modality for assessing steatosis hepatis based on qualitative image features of the liver. These include an echo-enhanced internal reflex pattern of the liver parenchyma, loss of signal in depth, blurred demarcation of the blood vessels and diaphragm, or areas of focal obesity. The sensitivity and specificity of conventional sonography is high in severe steatosis hepatis. On the other hand, the sensitivity is significantly worse in mild cases. In addition, intra- and interobserver reliability are poor in the assessment of steatosis hepatis of the conventional B-scan.

Quantitative ultrasound-based methods are the current standard of practice for point-of-care, noninvasive liver fat assessment. However, due to low penetration depth and confounding factors, invalid or poor-quality measurements are often encountered in large patients, or patients with liver fibrosis. In contrast to purely ultrasound-based approaches, thermoacoustic (TA) approaches are sensitive to tissue composition chemistry rather than acoustic scattering and/or attenuation, making TA measurements of liver fat content relatively insensitive to liver fibrosis or patient size.

Thermoacoustic (imaging) technology is non-invasive and combines short pulses of radio-frequency energy to create ultrasound signals (acoustic waves) in tissue to create images, or measurements, of fat in body tissues. The radio-frequency energy that is used to create thermoacoustic ultrasound signals is very similar to that used by cell phones and MRI scanners. Thermoacoustic signals are created in proportion to how well tissue is able to conduct electricity. Lean tissues are highly conductive while fatty tissues are not, and thus, thermoacoustics is able to differentiate lean and fatty tissues. A primary interest in detecting, and monitoring metabolic health, is measuring liver fat content. Thermoacoustic approaches to fat measurement in the liver have several unique advantages compared to other currently used technologies, including ultrasound and MRI. Medical ultrasound scanners are widely available but often have difficulty making high-quality images, and reliable measurements, in larger patients or deeper tissues. Thermoacoustic ultrasound signals are formed in the tissue allowing measurements of fat to be made at depths that may not be possible with conventional ultrasound systems. While MRI is the most accurate noninvasive method to estimate fat in tissue, it has limited availability and is very expensive compared to thermoacoustics, and thus impractical for widespread use that is needed to address the growing problem of fatty liver disease and metabolic syndrome.

Thermoacoustic approaches to fat measurement in tissue are exceptionally safe using radio frequency energy levels similar to MRI, with tissue heating that is less than a 0.001 degrees Celsius per pulse in temperature. ENDRA has developed a noninvasive bedside device called the TAEUS®-FLIP system for measuring fat in liver tissue. The TAEUS®-FLIP exam is performed during a routine exam and takes between 5-10 minutes to perform. The TAEUS®-FLIP system has the potential to bring wide access to accurate liver fat measurements to a wide range of patient populations and to address the unmet need for detecting and monitoring patients with fatty liver disease and metabolic syndrome.

In this study, the investigators want to compare TAEUS® FLIP with MRI-PDFF to gain insight into the potential of thermoacoustic methods to assess liver fat content, similar to MRI-PDFF. Unlike conventional quantitative ultrasound methods, the thermoacoustic approach has demonstrated the potential to obtain estimates of liver fat fraction in individuals with high BMI (45), and those with confirmed liver fibrosis.

Being tested
Thermoacoustic imaging, MRI and Ultrasound imaging
Keywords
MRI-PDFF, Thermoacoustics
Medical subject headings
Fatty Liver

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Thermoacoustic imaging, MRI and Ultrasound imagingDiagnostic test

    This is a Thermoacoustic imaging exam that will last 10-15 minutes. Distinguishing; assessment of steatosis liver disease in obese and morbidly obese patients.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Thermoacoustic Fat Measurements

    Perform thermoacoustic fat measurements for 80 participants, by one or more qualified operators, over the span of the study in order to determine the correlation of thermoacoustic derived fat fraction measures of steatotic liver disease to measurements obtained by MRI-PDFF.

    Measured: May 2024 to September 2025

  2. Estimate Accuracy of Thermoacoustic Fat Fraction

    Estimate the accuracy of thermoacoustic derived fat fraction measurements of steatotic liver disease by comparing to the established standard of MRI-PDFF measurements of liver fat fraction

    Measured: May 2024 to September 2025

Secondary outcomes (2)
  1. Usability Metric

    To derive usability in terms of exam failure rate, where a single exam failure is defined as a failure to produce a fat fraction value for the subject. Multiple qualified users will be trained to operate, and evaluate, the TAEUS® FLIP system usability.

    Measured: May 2024 to January 2025

  2. Estimate Operator Variability

    Estimate the intra- and inter- operator variability of thermoacoustic derived liver fat fraction in 10 participants, by acquiring fat fraction measurements in replicate, by multiple operators.

    Measured: May 2024 to January 2025

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted18 Apr 2024
  2. Study start21 Jun 2024 (estimated)
  3. Primary completion21 Jun 2025 (estimated)
  4. Study completion1 Sep 2025 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Cross-sectional
Enrolment
80 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06373536
Sponsor's protocol ID
LMU-RAD-01167
Status last verified
Apr 2024
First submitted
5 Apr 2024
Last updated
7 Jun 2024
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided: Data sharing is contingent on the data sharing policy of principal investigator and the study site.

Questions about this trial

What is this clinical trial studying?

An observational study of Steatosis of Liver, run by Endra Lifesciences at 1 site in Germany.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 7 Jun 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Germany. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Dirk-Andre Clevert, Prof. Dr. (+49 89 44007 3635, Dirk.Clevert@med.uni-muenchen.de), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Thermoacoustic Fat Measurements (time frame: May 2024 to September 2025). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 Jun 2024.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in